| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Filing example | MGX-001 Hemophilia A | IND | — | Small Molecules | Hematologic System | ||
IND Filing example | MGX-001 Hemophilia A | IND | — | Small Molecules | Hematologic System | ||
IND Filing example | MGX-001 Hemophilia A | IND | — | Small Molecules | Hematologic System |
Recent Updates
Recently added Catalysts
Metagenomi Therapeutics, Inc.$1.2
-0.04 (-3.2%)
Market Cap
50.82 M
EPS
-2.29
P/E Ratio
-
Value Trade
203.55 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.25 M
R&D Expenses
19.30 M
Operating CF
-21.18 M
Total Assets
196.95 M
Total Liabilities
59.17 M
Equity
137.78 M
D/E Ratio
12,345
1.5 %
Week
-10.6 %
1 Month
-10 %
3 Month
-10.6 %
6 Month
-86.83 %
5 Year
-86.83 %
All Time
Cash Data
Cash Position
140.16 M
Monthly Burn
7.06 M
Runway
18.9 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
63.49 K
52 Week Range
1.24 - 3.95
% held by Insiders
20.81 %
% held by Institutions
17.44 %
Enterprise Value
-50.15 M
Total Shares
37.52 M
Short %
6.14 %
Float Shares
22.51 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MGX-001 | Hemophilia A | Preclinical | 2025-08-13 | |||
MGX-001 | Hemophilia A | Preclinical | 2025-08-13 | |||
MGX-001 | Hemophilia A | Preclinical | 2025-08-13 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MGX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MGX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MGX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Metagenomi Therapeutics, Inc. (MGX) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How MGX ranks across every disease it competes in No competitive intelligence available for MGX.